These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33408257)

  • 21. Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.
    Circosta P; Vitaggio K; Elia AR; Todorovic M; Sangiolo D; Carnevale-Schianca F; Vallario A; Geuna M; Aglietta M; Cignetti A
    Immunotherapy; 2018 Jul; 10(9):753-767. PubMed ID: 30008257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.
    Li M; Sun K; Redelman D; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):739-50. PubMed ID: 20338256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
    Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
    J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
    Karimi MA; Bryson JL; Richman LP; Fesnak AD; Leichner TM; Satake A; Vonderheide RH; Raulet DH; Reshef R; Kambayashi T
    Blood; 2015 Jun; 125(23):3655-63. PubMed ID: 25788701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
    Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
    Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.
    Sauter CT; Bailey CP; Panis MM; Biswas CS; Budak-Alpdogan T; Durham A; Flomenberg N; Alpdogan O
    Bone Marrow Transplant; 2013 Sep; 48(9):1237-42. PubMed ID: 23624821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.
    Mohammadpour H; O'Neil R; Qiu J; McCarthy PL; Repasky EA; Cao X
    J Immunol; 2018 Apr; 200(7):2479-2488. PubMed ID: 29445008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
    Maloney DG
    Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
    Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
    Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.
    Griesenauer B; Jiang H; Yang J; Zhang J; Ramadan AM; Egbosiuba J; Campa K; Paczesny S
    J Immunol; 2019 May; 202(10):3053-3064. PubMed ID: 30979817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
    Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Synthetic CD8α:MyD88 Coreceptor Enhances CD8
    Kaczanowska S; Joseph AM; Guo J; Tsai AK; Lasola JJ; Younger K; Zhang Y; Gonzales CV; Davila E
    Cancer Res; 2017 Dec; 77(24):7049-7058. PubMed ID: 29055013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation.
    Robert S; Albring JC; Frebel K; Opitz C; Urh J; Wolf C; Heinrich C; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2018 Jul; 53(7):807-819. PubMed ID: 29362503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
    D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
    Front Immunol; 2020; 11():989. PubMed ID: 32528476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.
    Dertschnig S; Passweg J; Bucher C; Medinger M; Tzankov A
    Cell Immunol; 2023 Jul; 388-389():104719. PubMed ID: 37141843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor antigen-pulsed CD8α(+) dendritic cells induce T cell-mediated graft-versus-tumor effect in vitro.
    Na N; Chen K; Zhang J; He S; Fu Q; Zhu B; Cao K; Xu L
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):728-734. PubMed ID: 22173490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.